

0015

NOTES OF MEETING WITH DR CHRISTOPHER LUOLAM ON 23 AUGUST AT 2.00 PM

1. FEB noted the following stock situation:

- (a) 380 vials of PFC Factor VIII (approximately 84,000 units)
- (b) Commercial Factor VIII (Cutter) 200 vials at 250 units each (50,000 units)
- (c) Porcine Factor VIII ("Hyate") 18 vials at 585 units - to be returned by 20 October 1982 to manufacturers.
- (d) High purity Armour Factorate, kept in the Haematology Department - about 60 bottles of 550 units
- (e) Also 22 vials with 500 units of FEIBA is in stock in BTS.

NOTE - The above figures do not include cryoprecipitate in stock. Also the current stock of Factor VIII from PFC represents one month's debt to PFC, ie we have so far taken up the first three weeks stock for September.

- 2. FEB reminded CAL that the monthly allocations due from PFC of Factor VIII is 380 bottles until September (ie about 84,000 units); then from October the allocation will be reduced to 330 bottles (about 73,000 units).
- 3. FEB also noted that the clinical usage of PFC Factor VIII by the Haemophilia Centre is currently running at about 500-550 bottles a month.
- 4. FEB and CAL reviewed the expectations of Factor VIII on a pro rata basis:
 - (a) 5,000 Kgs per annum equals about 420 Kgs per month (plasma to PFC).
 - (b) On the simple pro rata scheme, this should equal 420 bottles FVIII per month to Edinburgh.
 - (c) Because of the deduction at source effect which FEB and BM are still pursuing with PFC, there has been the above mentioned reduction in expectations - ie from October 330 bottles per month.
- 5. CAL confirmed the following:
 - (a) The current usage rate of PFC Factor VIII is 95,000 - 130,000 units per month.
 - (b) [REDACTED], patient with ankle arthrodesis, is now using about 1,000 units of PFC Factor VIII twice a day - ie 10 bottles a day. He will arrange for this to be changed to cryoprecipitate dosage in the morning and PFC factor VIII only in the evening.
 - (c) He commented on the reluctance of the Haematology junior medical staff to use cryoprecipitate because of reactions - fevers, urticaria and bronchospasm.
 - (d) He gave advance notice that [REDACTED], 14 years old, with an acute knee haemarthrosis was being treated with cryoprecipitate and may require synovectomy in the coming weeks. No date yet fixed.

SNB.001.5208

2.

- (e) He confirmed his reluctance to use commercial factor VIII for [REDACTED] but he also confirmed that after the current usage of FEIBA no more should be purchased.

6. The following was agreed:

- (a) The 200 commercial bottles (or equivalent if exchanged with Glasgow Haemophilia Centre for PFC Factor VIII) should be maintained as the "bedrock" emergency stock.
- (b) CL will make additional efforts to keep within the monthly allocation from PFC.
- (c) FEB to continue exploring the possibilities of obtaining PFC Factor VIII from other regions - however he warned that this would be increasingly difficult and should not be relied upon.
- (d) FEB warned that there will almost certainly be a need to buy more commercial factor VIII if the current usage pattern continues.

The meeting ended at 3.00 pm.

GRO-C

F E Boulton

